BioCentury | Jul 7, 2017
Company News

Opiant gets rights to Aegis' Intravail delivery tech

...company Opiant Pharmaceuticals Inc. (OTCQB:OPNT) received rights to use the Intravail drug delivery system from Aegis Therapeutics LLC...
...Aegis Therapeutics LLC , San Diego, Calif. Opiant Pharmaceuticals Inc. (OTCQB:OPNT), Santa Monica, Calif. Business: Drug delivery Shannon Lehnbeuter Aegis Therapeutics LLC Opiant...
BioCentury | Feb 25, 2017
Finance

Intranasal option

...data in healthy volunteers are expected in April. The formulation uses drug delivery technology from Aegis Therapeutics LLC...
BioCentury | Feb 17, 2017
Financial News

Dauntless adds $25M to series A round

...DP1038 is an intranasal formulation of octreotide acetate which uses drug delivery technology from Aegis Therapeutics LLC...
BioCentury | Aug 24, 2015
Company News

Aegis Therapeutics, Dauntless Pharmaceuticals deal

...absorption enhancement agent for nasal drug delivery. The partners said financial terms are not disclosed. Aegis Therapeutics LLC...
BioCentury | Jul 27, 2015
Finance

Gestalt of the times

...which is developing DP1038 to treat endocrine cancers. DP1038 is in preclinical development and uses Aegis Therapeutics LLC's...
BioCentury | Jul 22, 2015
Financial News

Dauntless raises $12M series A

...$12 million series A round from Sofinnova Ventures and a deal with drug delivery company Aegis Therapeutics LLC...
BioCentury | Jun 18, 2012
Company News

Aegis Therapeutics, Biodel deal

...delivered in an auto-injector in preclinical development to treat insulin overdose. Details were not disclosed. Aegis Therapeutics LLC...
BioCentury | May 16, 2011
Company News

Aegis Therapeutics, Albany Medical College deal

...pregnancy hormone alpha fetoprotein (AFP) , is in preclinical testing. Financial terms were not disclosed. Aegis Therapeutics LLC...
BioCentury | Feb 1, 2010
Clinical News

Teriparatide: Phase I started

...50 healthy postmenopausal women. Zelos developed the intranasal formulation using Intravail permeation enhancer technology from Aegis Therapeutics LLC...
BioCentury | Dec 7, 2009
Company News

Aegis Therapeutics, Roche deal

...receive upfront fees and is eligible for milestones and royalties. Further terms were not disclosed. Aegis Therapeutics LLC...
Items per page:
1 - 10 of 19
BioCentury | Jul 7, 2017
Company News

Opiant gets rights to Aegis' Intravail delivery tech

...company Opiant Pharmaceuticals Inc. (OTCQB:OPNT) received rights to use the Intravail drug delivery system from Aegis Therapeutics LLC...
...Aegis Therapeutics LLC , San Diego, Calif. Opiant Pharmaceuticals Inc. (OTCQB:OPNT), Santa Monica, Calif. Business: Drug delivery Shannon Lehnbeuter Aegis Therapeutics LLC Opiant...
BioCentury | Feb 25, 2017
Finance

Intranasal option

...data in healthy volunteers are expected in April. The formulation uses drug delivery technology from Aegis Therapeutics LLC...
BioCentury | Feb 17, 2017
Financial News

Dauntless adds $25M to series A round

...DP1038 is an intranasal formulation of octreotide acetate which uses drug delivery technology from Aegis Therapeutics LLC...
BioCentury | Aug 24, 2015
Company News

Aegis Therapeutics, Dauntless Pharmaceuticals deal

...absorption enhancement agent for nasal drug delivery. The partners said financial terms are not disclosed. Aegis Therapeutics LLC...
BioCentury | Jul 27, 2015
Finance

Gestalt of the times

...which is developing DP1038 to treat endocrine cancers. DP1038 is in preclinical development and uses Aegis Therapeutics LLC's...
BioCentury | Jul 22, 2015
Financial News

Dauntless raises $12M series A

...$12 million series A round from Sofinnova Ventures and a deal with drug delivery company Aegis Therapeutics LLC...
BioCentury | Jun 18, 2012
Company News

Aegis Therapeutics, Biodel deal

...delivered in an auto-injector in preclinical development to treat insulin overdose. Details were not disclosed. Aegis Therapeutics LLC...
BioCentury | May 16, 2011
Company News

Aegis Therapeutics, Albany Medical College deal

...pregnancy hormone alpha fetoprotein (AFP) , is in preclinical testing. Financial terms were not disclosed. Aegis Therapeutics LLC...
BioCentury | Feb 1, 2010
Clinical News

Teriparatide: Phase I started

...50 healthy postmenopausal women. Zelos developed the intranasal formulation using Intravail permeation enhancer technology from Aegis Therapeutics LLC...
BioCentury | Dec 7, 2009
Company News

Aegis Therapeutics, Roche deal

...receive upfront fees and is eligible for milestones and royalties. Further terms were not disclosed. Aegis Therapeutics LLC...
Items per page:
1 - 10 of 19